ALFA Filings
Every announcement, straight from the exchange
Every Corona Remedies results update announcement on NSE and BSE, newest first, each with its own page.
Time
3 announcements
Corona Remedies released unaudited Q2 and H1 FY27 results highlights via press release. Revenue grew 22% year on year, with EBITDA and PAT also rising.
CORONA Remedies reported Q1FY27 Revenue of ₹422.4 Crore, up 21.9% Y-o-Y, and PAT of ₹60.1 Crore, up 30.1% Y-o-Y, highlighting resilient growth.
CORONA Remedies reported FY26 revenue of ₹1,403.2 Crore, representing 17.3% growth. PAT grew 33.4%, driven by strong brand building and the WOKADINE acquisition.